We’ve solved for science. What now?

The CGT field has achieved what once seemed impossible: the scientific capability to engineer sophisticated therapies with unprecedented precision. Yet as the pipeline grows, new challenges are emerging. FDA rejections are on the rise, quality lapses are more visible, and hard-won manufacturing advances don’t always translate into real-world access. 

What does the next chapter of this rapidly evolving field look like? How do we continue to translate scientific breakthroughs into safe, accessible, and scalable therapies? Join our panel of leading experts as they explore these questions, highlighting strategies in regulatory navigation, quality assurance, manufacturing optimization, and collaborative approaches to ensure that the next generation of therapies reaches the patients who need them most.